Bokor Éva, Kyriakis Efthimios, Solovou Theodora G A, Koppány Csenge, Kantsadi Anastassia L, Szabó Katalin E, Szakács Andrea, Stravodimos George A, Docsa Tibor, Skamnaki Vassiliki T, Zographos Spyros E, Gergely Pál, Leonidas Demetres D, Somsák László
Department of Organic Chemistry, University of Debrecen , POB 400, H-4002 Debrecen, Hungary.
Department of Biochemistry and Biotechnology, University of Thessaly, Biopolis , 41500 Larissa, Greece.
J Med Chem. 2017 Nov 22;60(22):9251-9262. doi: 10.1021/acs.jmedchem.7b01056. Epub 2017 Oct 3.
Aryl substituted 1-(β-d-glucosaminyl)-1,2,3-triazoles as well as C-β-d-glucosaminyl 1,2,4-triazoles and imidazoles were synthesized and tested as inhibitors against muscle and liver isoforms of glycogen phosphorylase (GP). While the N-β-d-glucosaminyl 1,2,3-triazoles showed weak or no inhibition, the C-β-d-glucosaminyl derivatives had potent activity, and the best inhibitor was the 2-(β-d-glucosaminyl)-4(5)-(2-naphthyl)-imidazole with a K value of 143 nM against human liver GPa. An X-ray crystallography study of the rabbit muscle GPb inhibitor complexes revealed structural features of the strong binding and offered an explanation for the differences in inhibitory potency between glucosyl and glucosaminyl derivatives and also for the differences between imidazole and 1,2,4-triazole analogues.
合成了芳基取代的1-(β-d-葡糖胺基)-1,2,3-三唑以及C-β-d-葡糖胺基1,2,4-三唑和咪唑,并作为糖原磷酸化酶(GP)肌肉和肝脏同工型的抑制剂进行了测试。虽然N-β-d-葡糖胺基1,2,3-三唑显示出较弱的抑制作用或无抑制作用,但C-β-d-葡糖胺基衍生物具有强效活性,最佳抑制剂是2-(β-d-葡糖胺基)-4(5)-(2-萘基)-咪唑,对人肝脏GPa的K值为143 nM。对兔肌肉GPb抑制剂复合物的X射线晶体学研究揭示了强结合的结构特征,并解释了葡糖基和葡糖胺基衍生物之间抑制效力的差异以及咪唑和1,2,4-三唑类似物之间的差异。